⌘K

08:12:12·1627d

SECFilingvia Quantisnow

Halozyme Therapeutics, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

ByQuantisnow·Wall Street's wire, on your screen.

HALO· Halozyme Therapeutics Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

SVP, CHIEF LEGAL OFFICER Snyder Mark Howard converted options into 5,034 shares and covered exercise/tax liability with 2,715 shares, increasing direct ownership by 5% to 49,929 units (SEC Form 4) to satisfy withholding obligation
Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
SEC Form 3 filed by new insider Snellgrove Darren
PRESIDENT AND CEO Torley Helen sold $3,370,008 worth of shares (50,000 units at $67.40) as part of a pre-agreed trading plan and exercised 50,000 shares at a strike of $12.07 (SEC Form 4)
Director Connaughton Bernadette sold $107,591 worth of shares (1,625 units at $66.21) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 43,669 units (SEC Form 4)